What are the therapeutic effects of Cabozantinib?

Cabozantinib (Cabozantinib) is an oral multi-target tyrosine kinase inhibitor (TKI) that has the ability to potently inhibit tumor angiogenesis and metastasis. It can target various signaling pathways such as VEGFR2, MET, AXL, RET, etc., thereby interfering with the growth, blood vessel formation, invasion and metastasis of cancer cells. Clinically, cabozantinib is widely used in the treatment of a variety of malignant tumors, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), and some pancreatic neuroendocrine tumors (pNET).

For patients with renal cell carcinoma, cabozantinib can significantly delay disease progression in advanced angiogenesis-dependent RCCRCC, and is considered an important treatment option after resistance to VEGFR inhibitors. In the treatment of hepatocellular carcinoma, cabozantinib is mainly used as a second-line regimen after failure of sorafenib treatment. Studies have shown that it has a significant effect in inhibiting the proliferation and metastasis of liver cancer cells. For patients with differentiated thyroid cancer (DTC), when radioactive iodine therapy is ineffective or ineffective, cabozantinib, as an inhibitor targeting the RET and VEGFR pathways, can effectively prolong progression-free survival. In addition, cabozantinib also shows potential anti-tumor activity in rare cancer types such as pancreatic neuroendocrine tumors (pNET), especially when used in combination with immune checkpoint inhibitors.

Different from traditional chemotherapy, cabozantinib works more precisely. It not only inhibits the tumor's nutritional and blood supply system, but also interferes with signal transduction in the tumor microenvironment, causing cancer cells to lose their ability to proliferate and invade. This multi-target mechanism enables it to demonstrate broad-spectrum efficacy in a variety of cancer types. It is worth noting that some studies are also exploring the prospects of its combined application with PD-1 inhibitors and mTOR inhibitors, providing more options for personalized targeted therapy in the future.

Reference:https://en.wikipedia.org/wiki/Cabozantinib